SCHEDULE 13G: ARCH Venture Funds Disclose 9.4% Stake in Maze Therapeutics
Beneficial Ownership Report
ARCH Venture Fund X and related entities, along with their key members, have disclosed a collective beneficial ownership of 9.4% in Maze Therapeutics, Inc., totaling 4,120,053 shares of common stock.
Summary
- ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, and individuals Keith Crandell, Robert Nelsen, Kristina Burow, and Steven Gillis (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The Reporting Persons collectively beneficially own 4,120,053 shares of common stock in Maze Therapeutics, Inc.
- This ownership represents 9.4% of Maze Therapeutics, Inc.'s common stock outstanding.
- The percentage is calculated based on 43,796,057 shares of common stock outstanding as of March 25, 2025, as reported in Maze Therapeutics' Form 10-K filed on March 31, 2025.
- The Reporting Persons hold shared voting power and shared dispositive power over all 4,120,053 beneficially owned shares.
Sentiment
Score: 5
Explanation: A Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. The significant stake by a reputable VC firm could be seen as a neutral to slightly positive signal of continued investor interest.
Positives
- A significant beneficial ownership stake of 9.4% by ARCH Venture Funds and their principals indicates continued confidence and investment in Maze Therapeutics, Inc.
Future Outlook
NA
Industry Context
This filing reflects a significant passive investment by a prominent venture capital firm, ARCH Venture Funds, in Maze Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector given the nature of venture capital investments in this space. Such filings are common for institutional investors holding substantial stakes in publicly traded companies.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.4% stake by ARCH Venture Funds may signal continued institutional confidence in Maze Therapeutics, potentially influencing investor perception and sentiment.
Key Dates
| Date | Description |
|---|---|
| 2021-06-16 | Date of filing of Power of Attorney for Mark McDonnell related to Verve Therapeutics, Inc. beneficial ownership, incorporated by reference. |
| 2025-03-25 | Date as of which 43,796,057 shares of common stock of Maze Therapeutics, Inc. were reported outstanding in the Issuer's Form 10-K. |
| 2025-03-31 | Date of event which requires filing of this statement; also the filing date of Maze Therapeutics, Inc.'s Form 10-K. |
| 2025-05-15 | Date of signing for the Schedule 13G filing and the Joint Filing Agreement. |
Keywords
Maze Therapeutics, ARCH Venture Fund, beneficial ownership, Schedule 13G, common stock, institutional investor, venture capital, biotechnology, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.